Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Miguel Sampayo
Observed names:
M Sampayo,
M. Sampayo
Institution:
MedSIR (Spain)
Observed institutions:
MedSIR (Spain),
Hospital Arnau de Vilanova,
Hospital Universitario Reina Sofía,
Hôpital Tenon,
Vall d'Hebron Institute of Oncology
ORCID:
0000-0003-1469-3410
Observed ORCID:
0000-0003-1469-3410
OpenAlex ID:
A5017040191
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
2021
·
Jordi Remon
, Nicolas Girard
, et al.
·
Clinical Lung Cancer
·
39
PDF
Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial
2019
·
A. Llombart Cussac
, J. Medioni
, et al.
·
Annals of Oncology
·
11
PDF
A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.
2013
·
Antonio Llombart-Cussac
, Xavier B. Pivot
, et al.
·
Journal of Clinical Oncology
·
8
P2.03-02 Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
2018
·
R. Palmero
, A. Taus
, et al.
·
Journal of Thoracic Oncology
·
4
Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.
2023
·
Xavier Garcia del Muro
, M. Andres Cuellar
, et al.
·
Journal of Clinical Oncology
·
3
66P Leptin receptor (Ob-R) and its association with tumour infiltrating lymphocytes (TILs) in early breast cancer (BC): Correlation with pathological complete response (pCR)
2021
·
L. García Estevez
, J. Palacios Calvo
, et al.
·
Annals of Oncology
·
2
Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.
2019
·
Jillian Bracht
, Niki Karachaliou
, et al.
·
Journal of Clinical Oncology
·
2
Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)
2018
·
José Manuel Pérez García
, Antonio Llombart
, et al.
·
Cancer Research
·
2
2273P Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
2023
·
M. González Rodríguez
, M. Fernadez Abad
, et al.
·
Annals of Oncology
·
1
PDF
2275P Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
2023
·
I. Calvo
, M.L. Argente
, et al.
·
Annals of Oncology
·
1
PDF
Abstract PS10-27: A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)
2021
·
Antonio Llombart-Cussac
, Javier Cortés
, et al.
·
Cancer Research
·
1
Multicenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study
2019
·
E. López-Miranda
, S. Di Cosimo
, et al.
·
Annals of Oncology
·
1
Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)
2018
·
N. Karachaliou
, M. Lefterova
, et al.
·
Annals of Oncology
·
1
Abstract P1-13-09: Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients
2016
·
A Llombart
, JR de la Haba-Rodríguez
, et al.
·
Cancer Research
·
1
Abstract P5-02-38: Leptin receptor (Ob-R)/leptin axis significantly modulates tumour-infiltrating lymphocytes (TILs) and PD-1 expression in early HER2+ breast cancer (BC) emerging as a new surrogate marker for immunotherapy
2023
·
Laura García-Estévez
, Adela Fernández
, et al.
·
Cancer Research
336TiP Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial
2021
·
A. Llombart Cussac
, J. Soberino
, et al.
·
Annals of Oncology
Abstract OT2-09-01: A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study)
2020
·
José Manuel Pérez-García
, Alfonso Cortés Salgado
, et al.
·
Cancer Research
Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial
2020
·
David Casadevall
, Joan Albanell Mestres
, et al.
·
Cancer Research
Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)
2020
·
José Manuel Pérez-García
, Antonio Llombart-Cussac
, et al.
·
Cancer Research
Abstract 449: Use of comprehensive cell-free circuating tumor DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed advanced non-small cell lung cancer (NSCLC) patients
2019
·
Ramon Palmero
, Alvaro Taus
, et al.
·
Clinical Research (Excluding Clinical Trials)
Abstract 449: Use of comprehensive cell-free circuating tumor DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed advanced non-small cell lung cancer (NSCLC) patients
2019
·
Ramon Palmero
, Alvaro Taus
, et al.
·
Cancer Research
Screening for Lynch syndrome among endometrial cancer patients less than 60 years
2016
·
E. Aguirre
, M. Mele
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
22
Citation count:
77
H-index:
4
I10-index:
2
Year
Topic
Type